Titre : Cyclic GMP-Dependent Protein Kinases

Cyclic GMP-Dependent Protein Kinases : Questions médicales fréquentes

Termes MeSH sélectionnés :

Network Meta-Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cyclic GMP-Dependent Protein Kinases : Questions médicales les plus fréquentes", "headline": "Cyclic GMP-Dependent Protein Kinases : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cyclic GMP-Dependent Protein Kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-11", "dateModified": "2025-04-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cyclic GMP-Dependent Protein Kinases" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Cyclic Nucleotide-Regulated Protein Kinases", "url": "https://questionsmedicales.fr/mesh/D017867", "about": { "@type": "MedicalCondition", "name": "Cyclic Nucleotide-Regulated Protein Kinases", "code": { "@type": "MedicalCode", "code": "D017867", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.150" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cyclic GMP-dependent protein kinase type I", "alternateName": "Cyclic GMP-Dependent Protein Kinase Type I", "url": "https://questionsmedicales.fr/mesh/D062965", "about": { "@type": "MedicalCondition", "name": "Cyclic GMP-dependent protein kinase type I", "code": { "@type": "MedicalCode", "code": "D062965", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.150.150.500" } } }, { "@type": "MedicalWebPage", "name": "Cyclic GMP-dependent protein kinase type II", "alternateName": "Cyclic GMP-Dependent Protein Kinase Type II", "url": "https://questionsmedicales.fr/mesh/D062967", "about": { "@type": "MedicalCondition", "name": "Cyclic GMP-dependent protein kinase type II", "code": { "@type": "MedicalCode", "code": "D062967", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.476.563.150.150.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Cyclic GMP-Dependent Protein Kinases", "alternateName": "Cyclic GMP-Dependent Protein Kinases", "code": { "@type": "MedicalCode", "code": "D017869", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Fengyang Li", "url": "https://questionsmedicales.fr/author/Fengyang%20Li", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Ute Römling", "url": "https://questionsmedicales.fr/author/Ute%20R%C3%B6mling", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Stepan Gambaryan", "url": "https://questionsmedicales.fr/author/Stepan%20Gambaryan", "affiliation": { "@type": "Organization", "name": "Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, Saint Petersburg 194223, Russia." } }, { "@type": "Person", "name": "Roshni R Kharadi", "url": "https://questionsmedicales.fr/author/Roshni%20R%20Kharadi", "affiliation": { "@type": "Organization", "name": "Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, Michigan, USA." } }, { "@type": "Person", "name": "George W Sundin", "url": "https://questionsmedicales.fr/author/George%20W%20Sundin", "affiliation": { "@type": "Organization", "name": "Department of Plant, Soil and Microbial Sciences, Michigan State University, East Lansing, Michigan, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Kenward-Roger-type corrections for inference methods of network meta-analysis and meta-regression.", "datePublished": "2023-07-03", "url": "https://questionsmedicales.fr/article/37399845", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jrsm.1652" } }, { "@type": "ScholarlyArticle", "name": "Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis.", "datePublished": "2024-09-18", "url": "https://questionsmedicales.fr/article/39293856", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1183/16000617.0046-2024" } }, { "@type": "ScholarlyArticle", "name": "Topical anti-inflammatory treatments for eczema: network meta-analysis.", "datePublished": "2024-08-06", "url": "https://questionsmedicales.fr/article/39105474", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD015064.pub2" } }, { "@type": "ScholarlyArticle", "name": "Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.", "datePublished": "2023-08-31", "url": "https://questionsmedicales.fr/article/37650547", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/14651858.CD013730.pub2" } }, { "@type": "ScholarlyArticle", "name": "Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36691161", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-063884" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines et peptides de signalisation intracellulaire", "item": "https://questionsmedicales.fr/mesh/D047908" }, { "@type": "ListItem", "position": 5, "name": "Protein-Serine-Threonine Kinases", "item": "https://questionsmedicales.fr/mesh/D017346" }, { "@type": "ListItem", "position": 6, "name": "Cyclic Nucleotide-Regulated Protein Kinases", "item": "https://questionsmedicales.fr/mesh/D017867" }, { "@type": "ListItem", "position": 7, "name": "Cyclic GMP-Dependent Protein Kinases", "item": "https://questionsmedicales.fr/mesh/D017869" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cyclic GMP-Dependent Protein Kinases - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cyclic GMP-Dependent Protein Kinases", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cyclic GMP-Dependent Protein Kinases", "description": "Comment diagnostiquer une dysfonction des kinases cGMP ?\nQuels tests sont utilisés pour mesurer le cGMP ?\nQuels symptômes indiquent un problème avec les kinases cGMP ?\nLes tests génétiques sont-ils utiles pour les kinases cGMP ?\nComment évaluer l'activité des kinases cGMP ?", "url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Network+Meta-Analysis&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cyclic GMP-Dependent Protein Kinases", "description": "Quels sont les symptômes d'une déficience en kinases cGMP ?\nLes troubles neurologiques sont-ils liés aux kinases cGMP ?\nComment les kinases cGMP affectent-elles la fonction cardiaque ?\nY a-t-il des symptômes spécifiques aux maladies liées aux kinases cGMP ?\nLes troubles de l'humeur peuvent-ils être liés aux kinases cGMP ?", "url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Network+Meta-Analysis&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cyclic GMP-Dependent Protein Kinases", "description": "Comment prévenir les troubles liés aux kinases cGMP ?\nL'alimentation influence-t-elle les kinases cGMP ?\nLe stress a-t-il un impact sur les kinases cGMP ?\nLes examens réguliers sont-ils importants ?\nL'exercice physique aide-t-il à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Network+Meta-Analysis&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cyclic GMP-Dependent Protein Kinases", "description": "Quels traitements ciblent les kinases cGMP ?\nLes médicaments augmentant le cGMP sont-ils efficaces ?\nComment les thérapies géniques peuvent-elles aider ?\nY a-t-il des traitements naturels pour les dysfonctionnements cGMP ?\nLes changements de mode de vie peuvent-ils aider ?", "url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Network+Meta-Analysis&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cyclic GMP-Dependent Protein Kinases", "description": "Quelles complications peuvent survenir avec des dysfonctionnements cGMP ?\nLes troubles de la coagulation sont-ils liés aux kinases cGMP ?\nY a-t-il des risques de cancer associés aux kinases cGMP ?\nLes maladies rénales peuvent-elles être influencées par cGMP ?\nLes troubles respiratoires sont-ils liés aux kinases cGMP ?", "url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Network+Meta-Analysis&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cyclic GMP-Dependent Protein Kinases", "description": "Quels sont les facteurs de risque pour les dysfonctionnements cGMP ?\nL'âge influence-t-il la fonction des kinases cGMP ?\nLe mode de vie sédentaire est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?", "url": "https://questionsmedicales.fr/mesh/D017869?mesh_terms=Network+Meta-Analysis&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dysfonction des kinases cGMP ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests biochimiques et des analyses génétiques peuvent être utilisés pour évaluer la fonction des kinases cGMP." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour mesurer le cGMP ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des dosages immunologiques et des tests enzymatiques peuvent mesurer les niveaux de cGMP dans les tissus." } }, { "@type": "Question", "name": "Quels symptômes indiquent un problème avec les kinases cGMP ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes variés comme des troubles cardiovasculaires ou neurologiques peuvent indiquer un dysfonctionnement." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils utiles pour les kinases cGMP ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier des mutations affectant les kinases cGMP." } }, { "@type": "Question", "name": "Comment évaluer l'activité des kinases cGMP ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'activité peut être évaluée par des essais enzymatiques spécifiques in vitro." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en kinases cGMP ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des troubles de la circulation sanguine et des problèmes de vision." } }, { "@type": "Question", "name": "Les troubles neurologiques sont-ils liés aux kinases cGMP ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans les kinases cGMP peuvent contribuer à des troubles neurologiques." } }, { "@type": "Question", "name": "Comment les kinases cGMP affectent-elles la fonction cardiaque ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles régulent la relaxation et la contraction cardiaque, influençant la pression artérielle." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux maladies liées aux kinases cGMP ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes spécifiques peuvent inclure des douleurs thoraciques et des palpitations." } }, { "@type": "Question", "name": "Les troubles de l'humeur peuvent-ils être liés aux kinases cGMP ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études suggèrent un lien entre les kinases cGMP et la régulation de l'humeur." } }, { "@type": "Question", "name": "Comment prévenir les troubles liés aux kinases cGMP ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Maintenir un mode de vie sain et surveiller les facteurs de risque cardiovasculaires aide à prévenir." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les kinases cGMP ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut soutenir la fonction des kinases cGMP." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur les kinases cGMP ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut affecter la signalisation cGMP et la santé cardiovasculaire." } }, { "@type": "Question", "name": "Les examens réguliers sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des examens réguliers peuvent aider à détecter précocement des dysfonctionnements cGMP." } }, { "@type": "Question", "name": "L'exercice physique aide-t-il à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut améliorer la signalisation cGMP et la santé globale." } }, { "@type": "Question", "name": "Quels traitements ciblent les kinases cGMP ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs spécifiques et des modulateurs de cGMP sont utilisés pour traiter certaines conditions." } }, { "@type": "Question", "name": "Les médicaments augmentant le cGMP sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments comme les nitrates et les inhibiteurs de la phosphodiestérase peuvent être efficaces." } }, { "@type": "Question", "name": "Comment les thérapies géniques peuvent-elles aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies géniques peuvent corriger des mutations dans les gènes des kinases cGMP." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour les dysfonctionnements cGMP ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certaines plantes médicinales peuvent avoir des effets bénéfiques sur la signalisation cGMP." } }, { "@type": "Question", "name": "Les changements de mode de vie peuvent-ils aider ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation saine et l'exercice peuvent améliorer la fonction des kinases cGMP." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des dysfonctionnements cGMP ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications peuvent inclure des maladies cardiovasculaires et des troubles neurologiques." } }, { "@type": "Question", "name": "Les troubles de la coagulation sont-ils liés aux kinases cGMP ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans les kinases cGMP peuvent affecter la coagulation sanguine." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés aux kinases cGMP ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Certaines études suggèrent un lien entre les dysfonctionnements cGMP et le développement du cancer." } }, { "@type": "Question", "name": "Les maladies rénales peuvent-elles être influencées par cGMP ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les kinases cGMP jouent un rôle dans la régulation de la fonction rénale." } }, { "@type": "Question", "name": "Les troubles respiratoires sont-ils liés aux kinases cGMP ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies dans la signalisation cGMP peuvent contribuer à des troubles respiratoires." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les dysfonctionnements cGMP ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'hypertension, le diabète et le tabagisme." } }, { "@type": "Question", "name": "L'âge influence-t-il la fonction des kinases cGMP ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut affecter la signalisation cGMP et la santé cardiovasculaire." } }, { "@type": "Question", "name": "Le mode de vie sédentaire est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire peut augmenter le risque de dysfonctionnement des kinases cGMP." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut perturber la signalisation cGMP et augmenter les risques de maladies." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies cardiovasculaires peuvent augmenter le risque." } } ] } ] }

Sources (10000 au total)

Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis.

With recent advancements in bronchoscopic procedures, data on the best modality to sample peripheral pulmonary lesions (PPLs) is lacking, especially comparing bronchoscopy with computed tomography-gui... We performed a meta-analysis, pairwise meta-analysis and network meta-analysis on studies reporting diagnostic yield and complications with the use of CT-TBNA, radial endobronchial ultrasound (rEBUS),... We included 363 studies. The overall pooled diagnostic yield was 78.1%, the highest with CT-TBNA (88.9%), followed by RAB (84.8%) and the least with rEBUS (72%). In the pairwise meta-analysis, only rE... Although CT-TBNA is the most effective approach to sample PPLs, RAB has a comparable diagnostic yield with a lesser complication rate. Further prospective studies are needed comparing CT-TBNA and RAB....

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. Topical anti-inflammatory treatments are used to control eczema symptoms, but the... To compare and rank the efficacy and safety of topical anti-inflammatory treatments for people with eczema using a network meta-analysis.... We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries on 29 June 2023, and checked the reference lists of included studies.... We included within-participant or between-participant randomised controlled trials (RCTs) in people of any age with eczema of any severity, but excluded trials in clinically infected eczema, seborrhoe... We used standard Cochrane methods. Primary outcomes were patient-reported eczema symptoms, clinician-reported eczema signs and investigator global assessment. Secondary outcomes were health-related qu... We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high-income countries in secondary care settings. Most studies included adults, wit... Potent TCS, JAK inhibitors and tacrolimus 0.1% were consistently ranked as amongst the most effective topical anti-inflammatory treatments for eczema and PDE-4 inhibitors as amongst the least effectiv...

Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.

Despite considerable improvement in outcomes for preterm infants, rates of bronchopulmonary dysplasia (BPD) remain high, affecting an estimated 33% of very low birthweight infants, with corresponding ... To determine whether differences in efficacy and safety exist between high-dose dexamethasone, moderate-dose dexamethasone, low-dose dexamethasone, hydrocortisone, and placebo in the prevention of BPD... We searched the Cochrane Library for all systematic reviews of systemic corticosteroids for the prevention of BPD and searched for completed and ongoing studies in the following databases in January 2... We included randomized controlled trials (RCTs) in preterm infants (< 37 weeks' gestation) at risk for BPD that evaluated systemic corticosteroids (high-dose [≥ 4 mg/kg cumulative dose] dexamethasone,... Our main information sources were the systematic reviews, with reference to the original manuscript only for data not included in these reviews. Teams of two paired review authors independently perfor... We included 59 studies, involving 6441 infants, in our analyses. Only six of the included studies provided direct comparisons between any of the treatment (dexamethasone or hydrocortisone) groups, for... Low-dose dexamethasone increased the risk for cerebral palsy (RR 1.92, 95% CI 1.12 to 3.28; moderate-certainty evidence) compared with control. Hydrocortisone may decrease the risk of major neurosenso... No effect was observed for the outcomes of major neurosensory disability or cerebral palsy. The evidence for the primary outcomes was of overall low certainty, with notable deductions for imprecision ... While early treatment with moderate-dose dexamethasone or late treatment with high-dose dexamethasone may lead to the best effects for survival without BPD, the certainty of the evidence is low. There...

Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis.

Severely calcified coronary stenoses are difficult to treat with percutaneous coronary interventions. The presence of severe calcifications complicates lesion preparation, advancement of stents and ac... We will conduct a systematic review of randomised trials enrolling patients with calcified coronary artery disease undergoing percutaneous coronary intervention. We will investigate any percutaneous t... No ethics approval is required for this study. The results will be published in a peer-reviewed journal in this field.... CRD42021226034....

Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability ... To compare adverse effects of immunotherapies for people with MS or clinically isolated syndrome (CIS), and to rank these treatments according to their relative risks of adverse effects through networ... We searched CENTRAL, PubMed, Embase, two other databases and trials registers up to March 2022, together with reference checking and citation searching to identify additional studies.... We included participants 18 years of age or older with a diagnosis of MS or CIS, according to any accepted diagnostic criteria, who were included in randomized controlled trials (RCTs) that examined o... We used standard Cochrane methods for data extraction and pairwise meta-analyses. For NMAs, we used the netmeta suite of commands in R to fit random-effects NMAs assuming a common between-study varian... This NMA included 123 trials with 57,682 participants... We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no importan...

Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.

A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM),... We searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials up to March 28, 2023. Network meta-analysis using a random-effects model was conducted to calculate risk r... A total of fourteen trials with 75,334 patients were analyzed. Among these, 40,956 had taken SGLT2 inhibitors and 34,378 had not. One of the main results with particular findings was empagliflozin use... Our network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrate... PROSPERO [CRD42022361906]....

A network meta-analysis of surgical treatments of complete rectal prolapse.

Surgical treatment of complete rectal prolapse can be undertaken via an abdominal or a perineal approach. The present network meta-analysis aimed to compare the outcomes of different abdominal and per... A PRISMA-compliant systematic review of PubMed, Scopus, and Web of Science was conducted. Randomized clinical trials comparing two or more procedures for the treatment of complete rectal prolapse were... Nine randomized controlled trials with 728 patients were included. The follow-up ranged between 12 and 47 months. Posterior mesh rectopexy had significantly lower odds of recurrence than did the Altem... Posterior mesh rectopexy ranked best with the lowest recurrence while perineal procedures ranked worst with the highest recurrence rates....

Efficacy and safety of COVID-19 vaccines: A network meta-analysis.

Several vaccines showed a good safety profile and significant efficacy against COVID-19. Moreover, in the absence of direct head to head comparison between COVID-19 vaccines, a network meta-analysis t... Databases PubMed, CENTRAL, medRxiv, and clinicaltrials.gov were searched. Studies were included if they were placebo-controlled clinical trials and reported the safety profile and/or effectiveness of ... Forty-nine clinical trials that included 421,173 participants and assessed 28 vaccines were included in this network meta-analysis. The network meta-analysis showed that Pfizer is the most effective i... We found that almost all of the vaccines included in this study crossed the threshold of 50% efficacy. However, some of them did not reach the previously mentioned threshold against the B.1.351 varian...